Cardioprotective medication use after renal transplantation

Kyle L. Dawson, Samir J. Patel, David Putney, Wadi N. Suki, A. Osama Gaber

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Cardiovascular disease is the leading cause of death in renal transplant patients. This study compares the use of cardioprotective medications in adult kidney transplant recipients at a single center with recommendations, which have been validated in the general population. Cardioprotective medication use was retrospectively collected post-renal transplant. Patients were defined as high risk if they had pre-transplant coronary heart disease or equivalent risk. "Optimal" treatment was defined as a patient receiving aspirin, statin, angiotensin-converting enzyme inhibitors/angiotensin receptor blocker, and a beta-blocker according to cardiovascular risk. The percentage of high-risk patients optimally treated at one, three, six, and 12 months was 7.7%, 11.5%, 17.6%, and 18.8%, respectively. Although the use of cardioprotective medications was evident in transplant recipients, opportunities exist to increase the use of optimal cardioprotective regimens after renal transplantation.

Original languageEnglish (US)
Pages (from-to)E253-E256
JournalClinical Transplantation
Issue number6
StatePublished - Nov 2010


  • Cardiovascular disease
  • Drug therapy
  • Kidney transplantation

ASJC Scopus subject areas

  • Transplantation


Dive into the research topics of 'Cardioprotective medication use after renal transplantation'. Together they form a unique fingerprint.

Cite this